Search the Newsreel

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

Tonix Pharmaceuticals Holding Corp. recently reported strong quarterly results, with revenues beating estimates by 75%. Following these results, analysts have significantly upgraded revenue estimates for 2026 and reduced loss estimates, though the consensus price target remains unchanged. The company is projected to see accelerated …

Tonix Pharmaceuticals Holding Corp. - Common Stock (NQ: TNXP

This article provides a collection of recent news headlines related to Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP). Key updates include Q2 2026 earnings highlights, the launch and sales performance of their fibromyalgia drug Tonmya, FDA interactions for a Lyme disease prevention drug, and various …

Tonix Pharmaceuticals (TNXP) Revenue Surge Meets Persistent Cash Burn Concerns

Tonix Pharmaceuticals (TNXP) reported a significant revenue surge in Q2 2026, driven by TONMYA sales, but also posted a substantial net loss, raising concerns about cash burn. Despite the revenue growth and early signs of product persistence, the company's heavy fixed costs and ongoing …

Tonix Pharma earnings beat by $0.27, revenue topped estimates

Tonix Pharma (NASDAQ: TNXP) announced its second-quarter earnings, reporting an EPS of $-2.4400, which surpassed analyst estimates by $0.27. The company's revenue of $13.54M also significantly exceeded the consensus estimate of $6.96M. Despite the strong earnings report, Tonix Pharma's stock has seen a decline …

Tonix Pharma Q2 Net Product Revenue Jumps On TONMYA Sales; Multiple Clinical Catalysts Ahead

(RTTNews) - Tonix Pharmaceuticals Holding Corp. (TNXP), a commercial-stage biopharmaceutical company, announced financial results for the quarter ended June 30, 2026, reflecting revenue growth driven mainly by the sales of the TONMYA drug for Fibromyalgia. In addition, the company provided an update on the …

Tonix Pharmaceuticals Holding Releases Q2 2026 Financial Results

Tonix Pharmaceuticals Holding Corp. reported its Q2 2026 financial results, showing a narrower loss per share and significantly increased revenue. The company posted a loss of $2.44 per share, outperforming analyst estimates, and revenue of $13.5M, a 577.9% increase year-over-year. This revenue growth was …

Tonix Pharmaceuticals Reports Second Quarter 2026 Financial Results and Operational Highlights

Tonix Pharmaceuticals reported strong second-quarter 2026 financial results, with TONMYA® net sales reaching $11 million, a 197% increase quarter-over-quarter. The company is expanding TONMYA's commercial reach and advancing its clinical pipeline, including a Phase 2 study for TNX-102 SL in major depressive disorder and …

Tonix Pharmaceuticals Holding Corp (TNXP) (Q2 2026) Earnings Call Highlights: TONMYA Surges ...

Key Points Interested in Tonix Pharmaceuticals Holding Corp.? Here are five stocks we like better. Tonmya drove strong commercial growth: Second-quarter net product revenue reached approximately $13.5 million, including $11 million from Tonmya, whose sales rose 197% sequentially. Prescriptions doubled from the prior quarter, …

Tonix outlines TNX-4800 Phase II with ~3,300 participants while scaling TONMYA to ~150 reps by September

Earnings Call Insights: Tonix Pharmaceuticals Holding Corp. (TNXP) Q2 2026 MANAGEMENT VIEW * “The launch of TONMYA is progressing well, supported by growing sales, improvement across launch metrics, and patient access wins,” said (Co-Founder, President, CEO & Chairman Seth Lederman), adding that TONMYA is …

Tonix Pharmaceuticals Q2 Earnings Call Highlights

Key Points Interested in Tonix Pharmaceuticals Holding Corp.? Here are five stocks we like better. Tonmya drove strong commercial growth: Second-quarter net product revenue reached approximately $13.5 million, including $11 million from Tonmya, whose sales rose 197% sequentially. Prescriptions doubled from the prior quarter, …

Is Tonix Pharmaceuticals (TNXP) Overvalued After Q2 Earnings Rep

Tonix Pharmaceuticals (NASDAQ:TNXP) Announces Earnings Results

Tonix Pharmaceuticals (NASDAQ:TNXP) reported its quarterly earnings, beating analyst expectations with an adjusted loss of $2.44 per share against an estimated $2.64 loss, and revenue of $13.54 million, surpassing the $7.72 million estimate. Despite positive earnings, the company remains deeply unprofitable with a negative …

Tonix Pharmaceuticals Holding Corp. 2Q 2026: Revenue $13.54M, EPS ($2.44) — 10-Q Summary

Tonix Pharmaceuticals Holding Corp. reported its second-quarter 2026 results, showing product revenue of $13.54 million, a significant increase from the previous year. The company recorded a net loss of $40.55 million and a loss per share of $2.44. Revenue growth was primarily driven by …

Tonix Pharmaceuticals posts $13.5M Q2 product revenue, $40.6M net loss

Tonix Pharmaceuticals reported second-quarter 2026 product revenue of $13.5 million and a net loss of $40.6 million. The company's cash and equivalents totaled $176.2 million as of June 30, 2026, with recent equity raises expected to fund operations into early Q2 2027. TONMYA net …

Tonix Pharmaceuticals Holding Corp (TNXP) Earnings Forecast: Future EPS & Revenue Growth Estimates

Insider Buyers At Tonix Pharmaceuticals Holding Recover Some Losses, But Still Down US$57k

Insiders at Tonix Pharmaceuticals Holding, despite a 20% price gain last week, are still down US$57k on their investments made over the past year. Co-Founder Seth Lederman made the largest purchase of US$223k, buying shares at a price higher than the current market value, …

TNXP Looks 587.4% Overvalued on GF Value™

Tonix Pharmaceuticals (NASDAQ: TNXP) is set to release its Q2 earnings report, with analysts forecasting a 286% year-over-year revenue surge despite ongoing losses. The company's Price-to-Sales ratio of 7.52 significantly exceeds historical and industry averages, indicating it is "Significantly Overvalued" according to GuruFocus' GF …

TONIX PHARMACEUTICALS HLDG Q2 2026 Earnings Preview: Recent $TNXP Insider Trading, Hedge Fund Activity, and More

Tonix Pharma CEO to speak at Canaccord Growth Conference fireside chat

Tonix Pharmaceuticals' CEO, Seth Lederman, is scheduled to speak at the Canaccord Genuity 46th Annual Growth Conference in Boston on August 11, 2026. He will also participate in one-on-one meetings at the Morgan Stanley 24th Annual Global Healthcare Conference in New York on September …

Tonix Pharmaceuticals Holding Corp. (TNXP) Stock Price, News, Quote & History

This page provides comprehensive financial information for Tonix Pharmaceuticals Holding Corp. (TNXP), including its current stock price, recent news, historical data, and company profile. It details the company's focus on developing therapies for CNS disorders, immunology, infectious diseases, and rare diseases, highlighting key products …

Tonix Pharmaceuticals to Present at Upcoming Investor Conferences, Highlighting TONMYA and Pipeline

Tonix Pharmaceuticals announced its participation in two upcoming investor conferences in August and September 2026, where President and CEO Dr. Seth Lederman will present and hold meetings. The company will highlight its recently approved flagship product, TONMYA, the first new fibromyalgia treatment in over …

Tonix CEO Seth Lederman to Take Part in Two Investor Events

Tonix Pharmaceuticals (Nasdaq: TNXP) announced that its President and CEO, Seth Lederman, M.D., will participate in two upcoming investor events. These include a fireside chat at the Canaccord Genuity 46th Annual Growth Conference on August 11, 2026, and 1x1 meetings at the Morgan Stanley …

Tonix publishes investor deck highlighting TONMYA fibromyalgia launch and pipeline updates

Tonix Pharmaceuticals released an investor deck detailing the launch of TONMYA for fibromyalgia and providing updates on its financial status and drug pipeline. TONMYA generated $3.7 million in Q1 2026 net sales and has been prescribed by over 2,600 prescribers since its November 2025 …

Tonix Pharmaceuticals Gets FDA Feedback for Lyme Disease Prevention Trial

Tonix Pharmaceuticals has received positive feedback from the FDA regarding its adaptive Phase 2 clinical trial design for TNX-4800, a long-acting monoclonal antibody aimed at preventing Lyme disease. This study plans to enroll approximately 3,300 adults and could potentially lead to the first immunopreventative …

Tonix Pharmaceuticals Announces FDA Alignment on Phase 2 Study Design for TNX-4800 Lyme Disease Prevention Trial

Tonix Pharmaceuticals (TNXP) has announced FDA alignment on the design of its Phase 2 study for TNX-4800, a long-acting monoclonal antibody for Lyme disease prevention. The study, set to begin in Q1 2027 and enroll approximately 3,300 adults in Lyme-endemic areas, aims to evaluate …

Tonix Plans Two-Dose Antibody Study; Protection Expected in 2 Days

Tonix Pharmaceuticals announced positive minutes from a Type C FDA meeting, confirming alignment on the design for an adaptive Phase 2 field study of TNX-4800, a monoclonal antibody for Lyme disease prevention. The study will enroll approximately 3,300 adults over two Lyme seasons, using …

Tonix Pharmaceuticals Announces FDA Alignment on 3,300‑Participant Adaptive Phase 2 Lyme Study; TNX-4800 Dosing, 2027 Site Delivery

Tonix Pharmaceuticals announced FDA alignment for a 3,300-participant adaptive Phase 2 field study of TNX-4800, focusing on Lyme disease prevention and safety over 52 weeks. The study will enroll adults in Lyme-endemic areas, with primary endpoints at six months and manufacturing on track for …

Tonix Pharmaceuticals (TNXP) 10K Form and Latest SEC Filings 2026

This article provides an overview of Tonix Pharmaceuticals' (TNXP) SEC filings, highlighting that the company has submitted over 726 documents since 2017. It details recent filings including a Form 8-K on August 3, 2026, and a Form 4 ownership change on July 9, 2026, …

Tonix Pharmaceuticals (TNXP) Expected to Release Earnings on Monday

TNXP|Tonix Pharmaceuticals Holding Corp|Price:9.510|Chg%:-0.430

This article provides a comprehensive stock analysis of Tonix Pharmaceuticals Holding Corp (TNXP) by TradingKey. It highlights the company's strong fundamentals, high growth potential, and current valuation as "fairly valued" within the pharmaceuticals industry. The report also notes high institutional ownership, positive analyst ratings …

Tonix Pharmaceuticals Holding Corp (TNXP) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of Tonix Pharmaceuticals Holding Corp (TNXP), highlighting major institutional investors and their holdings. Key shareholders include BlackRock, Point72, Vanguard, and Geode Capital. The report also provides a historical overview of institutional shareholding changes over recent quarters and lists …

Tonix Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 10, 2026

Tonix Pharmaceuticals Holding Corp. announced it will host a conference call and webcast on August 10, 2026, at 8:30 a.m. ET, to report its second-quarter 2026 financial results and operational highlights. The company, a commercial-stage biotechnology firm, specializes in CNS disorders, infectious diseases, immunology, …

Tonix to discuss second-quarter results on Aug. 10 call

Tonix Pharmaceuticals (Nasdaq: TNXP) announced it will host a conference call and webcast on August 10, 2026, at 8:30 a.m. ET to report its second-quarter 2026 financial results and operational highlights. Investors can register for the live event, and a replay will be available …